Activated protein C resistance: Prevalence and implications in peripheral vascular disease

Journal of Vascular Surgery

Volumn 23, Issue 1, 1996, Pages 46-52

  Ouriel, K ^a   Green, R M ^a   DeWeese, J A ^a   Cimino, C ^a   Wakefield, T W ^a   Lindblat, B ^a   Gillespie, D L ^a   Calligaro, K D ^a   Wolfe, J H N ^a   Dryjski, M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ANTICOAGULATION; ARTERY RECONSTRUCTION; CONFERENCE PAPER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; THROMBOGENESIS; TREATMENT OUTCOME; VASCULAR SURGERY;

EID: 0030043841     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-5214(05)80034-5     Document Type: Conference Paper

References (18)

1. Hennigan TW Vashisht R Young RA Protein C deficiency and rapidly progressing peripheral arterial disease Br J Surg 80 1993 466 469
2. Kario K Matsuo T Tai S Congenital protein C deficiency and myocardial infarction: concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis Thromb Res 67 1992 95 103
3. De Stefano V Leone G Micalizzi P Arterial thrombosis as clinical manifestation of congenital protein C deficiency Ann Hematol 62 1995 180 183
4. Dahlback B Carlsson M Svensson PJ Pamilial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C Proc Natl Acad Sci USA 90 1993 1004 1008
5. Svensson PJ Dahlbäck B Resistance to activated protein C as a basis for venous thrombosis N Engl J Med 330 1994 517 522
6. Koster T Rosendaal FR de Ronde H Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study Lancet 342 1993 1503 1506
7. Dahlbäck B Hildebrand B Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V Proc Natl Acad Sci USA 91 1994 1396 1400
8. Beauchamp NJ Baly ME Hampton KK High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis Br J Haematol 88 1994 219 222
9. Griffin JH Evatt B Wideman C Fernandez JA Anticoagulant protein C pathway defective in majority of thrombophilic patients Blood 82 1993 1989 1993
10. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
11. Peto R Pike MC Armitage P Design and analysis of randomized clinical trials requiring prolonged observation of each patient—II: analysis and examples Br J Cancer 35 1977 1 39
12. Becker RC Seminars in thrombosis, thrombolysis, and vascular biology—6: procoagulant stafes Cardiology 80 1992 51 64
13. Rosen S Johansson K Lindberg K Dahlback B Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals Thromb Haemost 72 1994 255 260
14. [letter] Cushman M Bhushan F Bovill E Plasma resistance to activated protein C in venous and arterial thrombosis Thromb Haemost 72 1994 647
15. Bertina RM Koeleman BP Koster T Mutation in blood coagulation factor V associated with resistance to activated protein C Nature 369 1994 64 67
16. Bokarewa M Blomback M Heterogeneity of the APC-resistance phenomenon Thromb Res 75 1994 395 400
17. [letter] Lindblad B Svensson PJ Dahlbäck B Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C Lancet 343 1994 917
18. Halbmayer WM Haushofer A Schon R Fischer M The prevalence of poor anticoagulant response to activated protein C among patients suffering from stroke or venous thrombosis and among healthy subjects Blood Coag Fibrinol 5 1994 51 57